Stock Analiz

Coya Therapeutics, Inc. COYA

Biotechnology: Pharmaceutical Preparations · IPO 2022 · data as of November 13, 2026

$3.13Market cap $73M
Open the interactive analysis →

Coya Therapeutics, Inc. (COYA) is a healthcare company listed in the US with a market value of about $73M. In the twelve months to September 30, 2026 it had revenue of $5M and net income of -$30M, a net margin of -643.5%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -52%.

About Coya Therapeutics

Coya Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2022. It was profitable in 0 of the last 5 years in our data. Its share count rose by 546% over three years (dilution for shareholders). It spends 211% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S15.7
P/B2.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-29.7%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)123.6%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-273.0%
ROIC (5-yr avg.)-51.5%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 5 years

Fiscal yearTTM20252024202320222021
Revenue$5M$8M$4M$6M$0—
Net income-$30M-$21M-$15M-$8M-$12M-$5M
Free cash flow-$22M-$11M-$10M-$11M-$7M-$4M
EPS (diluted)$-1.39$-1.27$-0.98$-0.79$-4.73$-1.89
Net margin-643.5%-267.1%-418.7%-133.1%——
ROIC—-41.4%-41.6%-17.5%—-105.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Coya Therapeutics pay a dividend?

Not currently.

Is Coya Therapeutics a good stock to buy?

We do not give buy or sell advice. Coya Therapeutics scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.